{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T04:43:04Z","timestamp":1776660184662,"version":"3.51.2"},"reference-count":104,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T00:00:00Z","timestamp":1679184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The clinical management of COVID-19 in pregnant women, who are considered a vulnerable population, remains uncertain even as the pandemic subsides. SARS-CoV-2 affects pregnant individuals in multiple ways and has been associated with severe maternal morbidity and mortality, as well as neonatal complications. The unique anatomy and physiology of gestation make managing COVID-19 in this population a complex and challenging task, emphasizing the importance of spreading knowledge and expertise in this area. Therapeutic interventions require distinct clinical consideration, taking into account differences in pharmacokinetics, vertical transmission, drug toxicities, and postnatal care. Currently, there is limited data on antiviral and immunomodulating COVID-19 pharmacotherapy in pregnancy. Some medication has been shown to be safe and well tolerated among pregnant women with COVID-19; however, the lack of randomized clinical trials and studies in this patient population is evident. Available vaccines are considered safe and effective, with no evidence of harm to the fetus, embryo development, or short-term postnatal development. Pregnant women should be counseled about the risks of SARS-CoV-2 infection and informed of available ways to protect themselves and their families. Effective treatments for COVID-19 should not be withheld from pregnant individuals, and more research is needed to ensure the best outcomes.<\/jats:p>","DOI":"10.3390\/v15030787","type":"journal-article","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T06:48:35Z","timestamp":1679294915000},"page":"787","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["COVID-19 Pharmacotherapy in Pregnancy: A Literature Review of Current Therapeutic Choices"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-9494","authenticated-orcid":false,"given":"Karolina","family":"Akinosoglou","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Patras, 26504 Patras, Greece"},{"name":"Department of Infectious Diseases, University General Hospital of Patras, 26504 Patras, Greece"},{"name":"Division of Internal Medicine, University General Hospital of Patras, 26504 Patras, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7963-1865","authenticated-orcid":false,"given":"Georgios","family":"Schinas","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Patras, 26504 Patras, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanouil-Angelos","family":"Rigopoulos","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Patras, 26504 Patras, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Polyzou","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Patras, 26504 Patras, Greece"},{"name":"Division of Internal Medicine, University General Hospital of Patras, 26504 Patras, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Argyrios","family":"Tzouvelekis","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Patras, 26504 Patras, Greece"},{"name":"Department of Pulmonology, University General Hospital of Patras, 26504 Patras, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2385-0871","authenticated-orcid":false,"given":"George","family":"Adonakis","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Patras, 26504 Patras, Greece"},{"name":"Department of Obstetrics and Gynecology, University General Hospital of Patras, 26504 Patras, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charalambos","family":"Gogos","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Patras, 26504 Patras, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.15585\/mmwr.mm6944e3","article-title":"Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status-United States, January 22\u2013October 3, 2020","volume":"69","author":"Zambrano","year":"2020","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Sessa, R., Filardo, S., Masciullo, L., Di Pietro, M., Angeloni, A., Brandolino, G., Brunelli, R., D\u2019Alisa, R., Viscardi, M.F., and Anastasi, E. (2023). SARS-CoV-2 Infection in Pregnancy: Clues and Proof of Adverse Outcomes. Int. J. Environ. Res. Public Health, 20.","DOI":"10.3390\/ijerph20032616"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1001\/jamapediatrics.2021.2606","article-title":"Further Observations on Pregnancy Complications and COVID-19 Infection-Reply","volume":"175","author":"Villar","year":"2021","journal-title":"JAMA Pediatr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"914.e1","DOI":"10.1016\/j.ajog.2020.06.022","article-title":"Coronavirus disease 2019 in pregnancy was associated with maternal morbidity and preterm birth","volume":"223","author":"Sentilhes","year":"2020","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1002\/hsr2.671","article-title":"Comparative evaluation of authorized drugs for treating COVID-19 patients","volume":"5","author":"Islam","year":"2022","journal-title":"Health Sci. Rep."},{"key":"ref_6","unstructured":"(2023, January 15). National Institutes of Health COVID-19 Treatment Guidelines, Available online: https:\/\/www.covid19treatmentguidelines.nih.gov\/."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Akinosoglou, K., Rigopoulos, E.A., Kaiafa, G., Daios, S., Karlafti, E., Ztriva, E., Polychronopoulos, G., Gogos, C., and Savopoulos, C. (2023). Tixagevimab\/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience. Viruses, 15.","DOI":"10.3390\/v15010118"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e3996","DOI":"10.1093\/cid\/ciaa1466","article-title":"Compassionate Use of Remdesivir in Pregnant Women with Severe Coronavirus Disease 2019","volume":"73","author":"Burwick","year":"2021","journal-title":"Clin Infect. Dis."},{"key":"ref_9","unstructured":"(2022, September 09). Center for Drug Evaluation and Research Clinical Review. NDA 214787. Remdesivir (Veklury), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/214787Orig1s010.pdf."},{"key":"ref_10","first-page":"267","article-title":"IMPAACT 2032: Remdesivir PK & Safety in Pregnant and Non-Pregnant Women with COVID-19","volume":"30","author":"Brooks","year":"2022","journal-title":"Top. Antivir. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/AOG.0000000000004734","article-title":"Early Administration of Remdesivir and Intensive Care Unit Admission in Hospitalized Pregnant Individuals with Coronavirus Disease 2019 (COVID-19)","volume":"139","author":"Eid","year":"2022","journal-title":"Obstet. Gynecol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Petrakis, V., Rapti, V., Akinosoglou, K., Bonelis, C., Athanasiou, K., Dimakopoulou, V., Syrigos, N.K., Spernovasilis, N., Trypsianis, G., and Marangos, M. (2022). Greek Remdesivir Cohort (GREC) Study: Effectiveness of Antiviral Drug Remdesivir in Hospitalized Patients with COVID-19 Pneumonia. Microorganisms, 10.","DOI":"10.3390\/microorganisms10101949"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.1080\/14767058.2021.1903426","article-title":"Pharmacological treatment in pregnant women with moderate symptoms of coronavirus disease 2019 (COVID-19) pneumonia","volume":"35","author":"Nasrallah","year":"2022","journal-title":"J. Matern. Fetal. Neonatal. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/1753495X211056211","article-title":"A review of COVID-19 therapeutics in pregnancy and lactation","volume":"15","author":"Jorgensen","year":"2022","journal-title":"Obstet. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/phar.2429","article-title":"Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19","volume":"40","author":"Jorgensen","year":"2020","journal-title":"Pharmacotherapy"},{"key":"ref_16","first-page":"171","article-title":"First Newborn Baby to Receive Experimental Therapies Survives Ebola Virus Disease","volume":"215","author":"Dornemann","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1542\/peds.2020-1701","article-title":"Infant with SARS-CoV-2 Infection Causing Severe Lung Disease Treated with Remdesivir","volume":"146","author":"Frauenfelder","year":"2020","journal-title":"Pediatrics"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/AOG.0000000000004900","article-title":"Short-term Pregnancy Outcomes After Nirmatrelvir-Ritonavir Treatment for Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)","volume":"140","author":"Loza","year":"2022","journal-title":"Obstet. Gynecol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e2244141","DOI":"10.1001\/jamanetworkopen.2022.44141","article-title":"Analysis of Clinical Outcomes of Pregnant Patients Treated with Nirmatrelvir and Ritonavir for Acute SARS-CoV-2 Infection","volume":"5","author":"Garneau","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1093\/cid\/ciac666","article-title":"Use of Ritonavir-Boosted Nirmatrelvir in Pregnancy","volume":"75","author":"Siberry","year":"2022","journal-title":"Clin Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"eabl7430","DOI":"10.1126\/scitranslmed.abl7430","article-title":"A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus","volume":"14","author":"Fischer","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"939573","DOI":"10.3389\/fphar.2022.939573","article-title":"Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial","volume":"13","author":"Zou","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_23","unstructured":"(2022, December 01). Food and Drug Administration Fact Sheet for Healthcare Providers: Emergency Use Authorization for Molnupiravir, Available online: https:\/\/www.fda.gov\/media\/155054\/download."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in Hospitalized Patients with COVID-19","volume":"384","author":"Group","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.2020.17022","article-title":"Effect of Hydrocortisone on Mortality and Organ Support in Patients with Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial","volume":"324","author":"Angus","year":"2020","journal-title":"JAMA"},{"key":"ref_26","unstructured":"(2020). The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients with COVID-19: A Meta-analysis. JAMA, 324, 1330\u20131341."},{"key":"ref_27","first-page":"240","article-title":"The clinical use of corticosteroids in pregnancy","volume":"22","author":"Kemp","year":"2016","journal-title":"Hum. Reprod Update"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/rheumatology\/kev404","article-title":"BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: Standard and biologic disease modifying anti-rheumatic drugs and corticosteroids","volume":"55","author":"Flint","year":"2016","journal-title":"Rheumatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1097\/AOG.0000000000002237","article-title":"Committee Opinion No. 713: Antenatal Corticosteroid Therapy for Fetal Maturation","volume":"130","year":"2017","journal-title":"Obstet. Gynecol."},{"key":"ref_30","unstructured":"(2022, December 20). Society for Maternal-Fetal Medicine Management Considerations for Pregnant Patients with COVID-19. Available online: https:\/\/s3.amazonaws.com\/cdn.smfm.org\/media\/2401\/SMFM_COVID_Management_of_COVID_pos_preg_patients_6-16-20._PDF.pdf."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.rdc.2017.04.013","article-title":"A Review of Systemic Corticosteroid Use in Pregnancy and the Risk of Select Pregnancy and Birth Outcomes","volume":"43","author":"Bandoli","year":"2017","journal-title":"Rheum. Dis. Clin North Am."},{"key":"ref_32","unstructured":"(2022, December 20). Bethesda MD Drugs and Lactation Database (LactMed), Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK501922\/."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 Receptor Antagonists in Critically Ill Patients with COVID-19","volume":"384","author":"Investigators","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.reprotox.2009.04.002","article-title":"Developmental toxicity testing of monoclonal antibodies: An enhanced pre- and postnatal study design option","volume":"28","author":"Stewart","year":"2009","journal-title":"Reprod. Toxicol."},{"key":"ref_35","unstructured":"Center for Drug Evaluation and Research Department of Health and Human Services Food and Drug Administration Actemra\u2122 (Tocilizumab) (2020, December 20). Pharmacology NDA Review and Evaluation, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/125472Orig1s000ClinPharmR.pdf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.semarthrit.2016.05.004","article-title":"Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data","volume":"46","author":"Hoeltzenbein","year":"2016","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"Hoeltzenbein","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/bdra.23003","article-title":"Teratogen update: Methotrexate","volume":"94","author":"Hyoun","year":"2012","journal-title":"Birth Defect. Res. A Clin. Mol. Teratol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3109\/14397595.2016.1147405","article-title":"Pregnancy outcomes after exposure to tocilizumab: A retrospective analysis of 61 patients in Japan","volume":"26","author":"Nakajima","year":"2016","journal-title":"Mod. Rheumatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/rheumatology\/kez100","article-title":"Tocilizumab during pregnancy and lactation: Drug levels in maternal serum, cord blood, breast milk and infant serum","volume":"58","author":"Saito","year":"2019","journal-title":"Rheumatology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/jcpt.13394","article-title":"Safety of tocilizumab in COVID-19 pregnant women and their newborn: A retrospective study","volume":"46","author":"Miarons","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"100407","DOI":"10.1016\/j.eclinm.2020.100407","article-title":"Incidence and clinical profiles of COVID-19 pneumonia in pregnant women: A single-centre cohort study from Spain","volume":"23","author":"Barbero","year":"2020","journal-title":"EClinicalMedicine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/AOG.0000000000004050","article-title":"Tocilizumab and Remdesivir in a Pregnant Patient with Coronavirus Disease 2019 (COVID-19)","volume":"136","author":"Naqvi","year":"2020","journal-title":"Obstet. Gynecol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cmi.2021.08.016","article-title":"Tocilizumab for coronavirus disease 2019 in pregnancy and lactation: A narrative review","volume":"28","author":"Jorgensen","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3390\/nu3040442","article-title":"Perspectives on immunoglobulins in colostrum and milk","volume":"3","author":"Hurley","year":"2011","journal-title":"Nutrients"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0890334405280652","article-title":"Immunologic factors in human milk: The effects of gestational age and pasteurization","volume":"21","author":"Koenig","year":"2005","journal-title":"J. Hum. Lact."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/1756-185X.13557","article-title":"Clinical application of the dried milk spot method for measuring tocilizumab concentrations in the breast milk of patients with rheumatoid arthritis","volume":"22","author":"Saito","year":"2019","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1093\/rheumatology\/key091","article-title":"Tocilizumab concentrations in maternal serum and breast milk during breastfeeding and a safety assessment in infants: A case study","volume":"57","author":"Saito","year":"2018","journal-title":"Rheumatology"},{"key":"ref_49","unstructured":"Public Health on England UK Teratology Information Service (2022, December 20). Use of Tocilizumab in Pregnancy. Available online: https:\/\/www.medicinesinpregnancy.org\/bumps\/monographs\/USE-OF-TOCILIZUMAB-IN-PREGNANCY\/."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/phar.2438","article-title":"Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19","volume":"40","author":"Jorgensen","year":"2020","journal-title":"Pharmacotherapy"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus Remdesivir for Hospitalized Adults with COVID-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): A randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_53","unstructured":"(2022, December 20). Center for Drug Evaluation and Research Pharmacology Review. NDA 207924. Baricitinib (Olumiant), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/207924Orig1s000PharmR.pdf."},{"key":"ref_54","unstructured":"(2022, December 20). Center for Drug Evaluation and Research Medical Review. NDA 207924. Baricitinib (Olumiant), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/207924Orig1s000MedR.pdf."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1759720X19899296","DOI":"10.1177\/1759720X19899296","article-title":"Baricitinib exposure during pregnancy in rheumatoid arthritis","volume":"12","author":"Costanzo","year":"2020","journal-title":"Ther. Adv. Musculoskelet Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"101785","DOI":"10.1016\/j.eclinm.2022.101785","article-title":"Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: A subgroup analysis of the SAVE-MORE randomised trial","volume":"56","author":"Akinosoglou","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","article-title":"Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: A double-blind, randomized controlled phase 3 trial","volume":"27","author":"Kyriazopoulou","year":"2021","journal-title":"Nat. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1136\/ard.2008.105833","article-title":"A patient\u2019s wish: Anakinra in pregnancy","volume":"68","author":"Berger","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1002\/art.38811","article-title":"Anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes (CAPS)","volume":"66","author":"Chang","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"66","DOI":"10.5152\/eurjrheum.2017.16075","article-title":"Anakinra use during pregnancy: Report of a case with Familial Mediterranean Fever and infertility","volume":"4","author":"Ilgen","year":"2017","journal-title":"Eur. J. Rheumatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1093\/rheumatology\/key093","article-title":"Five successful pregnancies with antenatal anakinra exposure","volume":"57","author":"Smith","year":"2018","journal-title":"Rheumatology"},{"key":"ref_62","first-page":"1","article-title":"Can Anakinra and corticosteroid treatment be an effective option in pregnant women with severe COVID-19?","volume":"61","author":"Erden","year":"2021","journal-title":"Women Health"},{"key":"ref_63","unstructured":"(2022, December 01). FDA Fact Sheet for Health Care Providers: Emergency Use Authorization for Kineret. Available online: https:\/\/bit.ly\/3ETiFXQ."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1111\/jog.15338","article-title":"Evaluation of the tolerability of monoclonal antibody therapy for pregnant patients with COVID-19","volume":"48","author":"Magawa","year":"2022","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ajog.2022.01.018","article-title":"A real-world assessment of tolerability and treatment outcomes of COVID-19 monoclonal antibodies administered in pregnancy","volume":"226","author":"Chang","year":"2022","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_66","unstructured":"(2022, February 01). Available online: https:\/\/www.fda.gov\/media\/154701\/download."},{"key":"ref_67","unstructured":"American College of Obstetricians and Gynecologists (2022, September 15). COVID-19 Vaccination Considerations for Obstetric\u2013Gynecologic Care. Available online: https:\/\/www.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2020\/12\/covid-19-vaccination-considerations-for-obstetric-gynecologic-care?utm_source=higher-logic&utm_medium=email&utm_content=sept-14&utm_campaign=acog2022-digest."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1093\/cid\/ciac135","article-title":"The Effect of Gestational Age at BNT162b2 mRNA Vaccination on Maternal and Neonatal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Levels","volume":"75","author":"Rottenstreich","year":"2022","journal-title":"Clin Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/AOG.0000000000004693","article-title":"Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose with Maternal and Umbilical Cord Antibody Levels at Delivery","volume":"139","author":"Yang","year":"2022","journal-title":"Obstet. Gynecol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e074035","DOI":"10.1136\/bmj-2022-074035","article-title":"Canadian Immunization Research Network Provincial Collaborative Network, I. Maternal mRNA COVID-19 vaccination during pregnancy and delta or omicron infection or hospital admission in infants: Test negative design study","volume":"380","author":"Jorgensen","year":"2023","journal-title":"BMJ"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Corsi Decenti, E., Salvatore, M.A., Mandolini, D., Donati, S., and Italian Obstetric Surveillance System COVID-19 Working Group (Clin. Microbiol. Infect., 2023). Vaccination against SARS-CoV-2 in pregnancy during the Omicron wave: The prospective cohort study of the Italian obstetric surveillance system, Clin. Microbiol. Infect., in press.","DOI":"10.1016\/j.cmi.2023.01.013"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1038\/s41467-022-30052-w","article-title":"Systematic review and meta-analysis of the effectiveness and perinatal outcomes of COVID-19 vaccination in pregnancy","volume":"13","author":"Prasad","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2204399","article-title":"Maternal Vaccination and Risk of Hospitalization for COVID-19 among Infants","volume":"387","author":"Halasa","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41591-021-01666-2","article-title":"SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland","volume":"28","author":"Stock","year":"2022","journal-title":"Nat. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"26","DOI":"10.15585\/mmwr.mm7101e1","article-title":"Receipt of COVID-19 Vaccine During Pregnancy and Preterm or Small-for-Gestational-Age at Birth-Eight Integrated Health Care Organizations, United States, December 15, 2020\u2013July 22, 2021","volume":"71","author":"Lipkind","year":"2022","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(21)02282-0","article-title":"Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination","volume":"398","author":"Hillson","year":"2021","journal-title":"Lancet"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ijid.2023.01.018","article-title":"The Dose-and Time-Dependent Effectiveness and Safety Associated with COVID-19 Vaccination During Pregnancy: A Systematic Review and Meta-analysis","volume":"128","author":"Wu","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/aje\/kwac011","article-title":"A Prospective Cohort Study of COVID-19 Vaccination, SARS-CoV-2 Infection, and Fertility","volume":"191","author":"Wesselink","year":"2022","journal-title":"Am. J. Epidemiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/humrep\/deab238","article-title":"Effects of COVID-19 and mRNA vaccines on human fertility","volume":"37","author":"Chen","year":"2021","journal-title":"Hum. Reprod."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/AOG.0000000000004713","article-title":"In Vitro Fertilization and Early Pregnancy Outcomes After Coronavirus Disease 2019 (COVID-19) Vaccination","volume":"139","author":"Aharon","year":"2022","journal-title":"Obstet. Gynecol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1054273","DOI":"10.3389\/fimmu.2022.1054273","article-title":"Safety of COVID-19 vaccination in women undergoing IVF\/ICSI treatment-Clinical study and systematic review","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1055\/s-0042-1748158","article-title":"COVID-19 Vaccinations in Pregnancy: Comparative Evaluation of Acute Side Effects and Self-Reported Impact on Quality of Life between Pregnant and Nonpregnant Women in the United States","volume":"39","author":"Brinkley","year":"2022","journal-title":"Am. J. Perinatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1056\/NEJMc2205276","article-title":"Evaluation of Acute Adverse Events after COVID-19 Vaccination during Pregnancy","volume":"387","author":"DeSilva","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1056\/NEJMc2113891","article-title":"Receipt of mRNA COVID-19 Vaccines and Risk of Spontaneous Abortion","volume":"385","author":"Zauche","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ijgo.14008","article-title":"Systematic review of the safety, immunogenicity, and effectiveness of COVID-19 vaccines in pregnant and lactating individuals and their infants","volume":"156","author":"Fu","year":"2022","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Gray, K.J., Bordt, E.A., Atyeo, C., Deriso, E., Akinwunmi, B., Young, N., Baez, A.M., Shook, L.L., Cvrk, D., and James, K. (2021). COVID-19 vaccine response in pregnant and lactating women: A cohort study. medRxiv.","DOI":"10.1101\/2021.03.07.21253094"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.2021.7563","article-title":"Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women","volume":"325","author":"Collier","year":"2021","journal-title":"JAMA"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/AOG.0000000000004621","article-title":"Maternal Outcomes After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Vaccinated Compared with Unvaccinated Pregnant Patients","volume":"139","author":"Morgan","year":"2022","journal-title":"Obstet. Gynecol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1001\/jamapediatrics.2022.0001","article-title":"Association of BNT162b2 COVID-19 Vaccination During Pregnancy with Neonatal and Early Infant Outcomes","volume":"176","author":"Goldshtein","year":"2022","journal-title":"JAMA Pediatr."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1001\/jama.2022.4255","article-title":"Association of COVID-19 Vaccination in Pregnancy with Adverse Peripartum Outcomes","volume":"327","author":"Fell","year":"2022","journal-title":"JAMA"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jama.2022.3271","article-title":"Association of SARS-CoV-2 Vaccination During Pregnancy with Pregnancy Outcomes","volume":"327","author":"Magnus","year":"2022","journal-title":"JAMA"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/jamapediatrics.2022.0164","article-title":"Association of COVID-19 Vaccination During Early Pregnancy with Risk of Congenital Fetal Anomalies","volume":"176","author":"Ruderman","year":"2022","journal-title":"JAMA Pediatr."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"100637","DOI":"10.1016\/j.ajogmf.2022.100637","article-title":"Safety of third SARS-CoV-2 vaccine (booster dose) during pregnancy","volume":"4","author":"Dick","year":"2022","journal-title":"Am. J. Obstet. Gynecol. MFM"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Hagrass, A.I., Almadhoon, H.W., Al-Kafarna, M., Almaghary, B.K., Nourelden, A.Z., Fathallah, A.H., Hasan, M.T., Mohammed, Y.A., Al-Nabahin, A.O., and Wafi, D.S. (2022). Maternal and neonatal safety outcomes after SAR-CoV-2 vaccination during pregnancy: A systematic review and meta-analysis. BMC Pregnancy Childbirth, 22.","DOI":"10.1186\/s12884-022-04884-9"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1016\/j.vaccine.2022.09.019","article-title":"The impact of COVID-19 vaccines on fertility-A systematic review and meta-analysis","volume":"40","author":"Zace","year":"2022","journal-title":"Vaccine"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1001\/jamapediatrics.2022.3456","article-title":"Peripartum Outcomes Associated with COVID-19 Vaccination During Pregnancy: A Systematic Review and Meta-analysis","volume":"176","author":"Watanabe","year":"2022","journal-title":"JAMA Pediatr."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Hui, L., Marzan, M.B., Rolnik, D.L., Potenza, S., Pritchard, N., Said, J.M., Palmer, K.R., Whitehead, C.L., Sheehan, P.M., and Ford, J. (2022). Reductions in stillbirths and preterm birth in COVID-19-vaccinated women: A multicenter cohort study of vaccination uptake and perinatal outcomes. Am. J. Obstet. Gynecol.","DOI":"10.1101\/2022.07.04.22277193"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Huang, J., Fang, Z., Liu, Y., Xing, C., Huang, L., Mao, J., Chen, H., Huang, Z., Xia, L., and Tang, L. (2023). Effect of female COVID-19 vaccination on assisted reproductive outcomes: A systematic review and meta-analysis. Fertil. Steril., Epub ahead of print.","DOI":"10.1016\/j.fertnstert.2023.01.024"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"777103","DOI":"10.3389\/fimmu.2021.777103","article-title":"COVID-19 mRNA Vaccination in Lactation: Assessment of Adverse Events and Vaccine Related Antibodies in Mother-Infant Dyads","volume":"12","author":"Golan","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41541-021-00370-z","article-title":"Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees","volume":"6","author":"Low","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Kontovazainitis, C.G., Katsaras, G.N., Gialamprinou, D., and Mitsiakos, G. (2023). COVID-19 vaccination and pregnancy: A systematic review of maternal and neonatal outcomes. J. Perinat. Med.","DOI":"10.17504\/protocols.io.b4zhqx36"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e007730","DOI":"10.1136\/bmjgh-2021-007730","article-title":"Global disparities in public health guidance for the use of COVID-19 vaccines in pregnancy","volume":"7","author":"Zavala","year":"2022","journal-title":"BMJ Glob. Health"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Gunawardhana, N., Baecher, K., Boutwell, A., Pekwarake, S., Kifem, M., Ngong, M.G., Fondzeyuf, A., Halle-Ekane, G., Mbah, R., and Tih, P. (2022). COVID-19 vaccine acceptance and perceived risk among pregnant and non-pregnant adults in Cameroon, Africa. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0274541"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Varlas, V.N., Bors, R.G., Plotogea, M., Iordache, M., Mehedintu, C., and Cirstoiu, M.M. (2023). Thromboprophylaxis in Pregnant Women with COVID-19: An Unsolved Issue. Int. J. Environ. Res. Public Health, 20.","DOI":"10.3390\/ijerph20031949"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/3\/787\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:58:54Z","timestamp":1760122734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/3\/787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,19]]},"references-count":104,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["v15030787"],"URL":"https:\/\/doi.org\/10.3390\/v15030787","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,19]]}}}